Extensive allele diversity is observed in HLA associations with response to HCV combined therapy (pegylated interferon + ribavitin) in different global ethnic populations. The aim of the study is to assess the frequency and association of certain HLA-class I alleles in Egyptian persons with persistent HCV and others with sustained viral response (SVR).
Introduction
Viral genotype, host genetic background and HLA class I-and class II-alleles are associated with both HCV disease progression and sustained response to therapy [8] . MHC class I molecules play a crucial role in initiating potentially protective immune responses by presenting intracellular pathogen-derived peptides to CD8 + T cells and thus targeting infected cells for elimination [9] . In HCV infection, recognition and elimination of infected cells by cytotoxic T lymphocytes (CTLs) require the presentation of specific HCV antigens on the membrane of hepatocytes in the context of HLA-A, -B and -C antigens. MHC class I molecules are highly polymorphic, but HLA-B is the most diverse class I locus and the most polymorphic gene of the human genome [11] . Furthermore, HLA-B-restricted pathogen-derived epitopes seem to be more frequently targeted by CD8 + T cells than those presented on HLA-A. Additionally, HLA-B-dictated T cell responses seem to be of higher magnitude [6, 1] and have been described to influence infectious disease course and outcome.
For these reasons HLA-B alleles may be major determinants of the effectiveness of immune responses against pathogens because the responses they elicit are dominant [9] . Previous studies demonstrate associations of genes encoding HLA-class I antigens with the outcome of HCV infection. Some associations are race and geography dependent. Interferon therapy involves adverse effects; HLA studies will help identifying responder/non responder markers that would help select patients suitable for interferon therapy.
The relation between HCV viral load and HLA class I type was previously studied by some Egyptian researchers [7] . The aim of the present study is to assess the frequency and association of certain HLA-class I alleles in Egyptian persons with persistent HCV and others with sustained viral response (SVR).
Material and methods

Type of the study
The study was a retrospective cohort study of HCV infected patients who received Peg-IFN plus ribavirin combined therapy. Our study did not include healthy control group.
Subjects
The participants were recruited from the Liver Institute of Cairo University, Egypt. All the participants in the present study were from HCV patients who received combined therapy in the Liver Institute of Cairo University. The participants were divided according to standard criteria into: -140 chronic HCV patients (non-responder to Interferon therapy). -106 resolved HCV cases: sustained viral response (SVR).
The aim of this study is to assess the frequency and association of certain HLA class I alleles with viral clearance or persistence of HCV infection after Peg-IFN plus ribavirin therapy. Patients were treated by either pegylated or shortacting interferon along with ribavirin according to Formann et al. [3] .
Laboratory investigations
The presence of HCV antibodies was determined by thirdgeneration enzyme linked immunosorbent assay ELISA;
CTK-Bioteck-USA), liver function tests including ALT (alanine transaminase), AST (aspartate transaminase), ALP (alkaline phosphatase) and albumin were assayed using Olympus auto analyzer AU400 (Olympus Diagnostica, Japan). 
HLA class I typing
Genomic DNA was extracted from peripheral blood mononuclear cells using the QIAmp DNA minikit (Qiagen) according to the manufacturer's instructions. HLA class I (A, B, and C) typing was performed by sequence-specific oligonucleotide probe protocols using LABTypeÒ SSO Typing kit (ONE LAMBDA,INC): LABTypeÒ applies LuminexÒ technology to the reverse SSO DNA typing method according to the manufacturer's instructions.
Statistical analysis
Statistical analyses were carried out using ''Statistical Package for Social Science (SPSS) Inc., Chicago, IL, USA'' (SPSS Version 18). Qualitative data were expressed in number and percent. Chi-square test ''v 2 ''was used for comparing groups, and Odds ratio (OR) was used to study the association between the different alleles and the prognosis of HCV infections. Likelihood ratio was used if the expected values of >25 of the cells are less than 5. Data that were significant according to univariate analysis were then entered in logistic regression analysis to determine the predictable variable that can affect the response to interferon treatment. We considered P-value to be significant at P < 0.05 with 95% confidence interval (CI).
Results
This study includes 246 patients with HCV infection who received combined therapy; 106 resolved HCV (SVR) cases and 140 chronic HCV cases (non responder). The age of participants ranged between 20 and 50 years and the duration of HCV infection ranged between 2 and 20 years.
The results of HCV genotyping revealed HCV genotype 4 (20%), and its subtypes 4c/4d (75%), 4e (1%) and 4h (4%). No relation was found between HCV genotypes and HLA types.
In our study we detected 18 alleles at the A locus. The percent of positive HLA-A alleles are shown in Table 1 . There was no significant difference between the frequencies of the positive alleles in non responder and in the SVR patients, except in HLA-A*32. The frequency of HLA-A*32 was significantly higher in the SVR cases compared to the non responder cases.
In the present study, 29 alleles at the B locus were detected. The percent of the positive HLA-B alleles are shown in Table 2 .
The frequencies of positive HLA-B\8 and HLA-B\53 were significantly higher in SVR patients compared to the non responder cases. Additionally, B\37 seemed to be associated with the SVR cases by 4.1 times more than in the non responder cases, even there was no statistical significant difference detected.
Regarding the C allele, 14 alleles were identified at the C locus. The percent of the positive HLA-C alleles are shown in Table 3 . The frequency of HLA-Cw\17 was significantly higher in non responder cases compared to the SVR cases, but Odds ratio (OR) was less than 1. This means that the absence of allele HLA-Cw\17 can be weakly used for testing for the prognosis of the treatment.
According to the strength of the predictive value: Logistic regression was used as shown in Table 4 to detect the significant predictor alleles for the response of HCV infected cases to interferon treatment. According to logistic regression analysis, HLA-A alleles might have a limited predictor role of SVR among HCV cases, as none of the A alleles have significant relation to the response to interferon treatment. Whereas, the presence of the HLA-B45 and HLA-B27 alleles has a 19.35-fold risk and 15.7 fold risk respectively of non-response to interferon therapy in chronic HCV patients (OR = 19.35; 95% CI: 1.05-357.24; P = 0.04) and (OR = 15.69; 95% CI: 1.179-208.9; P = 0.04). But, Cw17 was considered as the most significant predictor allele as it was the highest significant allele (OR = 16.70; 95% CI: 2.64-105.58; P = 0.003). These three alleles can act as the highest predictor alleles for the nonresponders to the combined therapy. The lowest significant predictor allele was B44 (OR = 6.535; 95% CI: 1.55-27.63; P = 0.01), with a constant À36.14.
Discussion
The mechanism of HCV pathogenesis remains elusive. Interplay of HLA restricted T lymphocytes, antibody-secreting Impact of HLA-class I alleles on response to HCV treatment in a cohort of Egyptian patients B-lymphocytes, NK cells and cytokines, conditions the immune response to viral infections. Effective presentation of viral antigens to CD4 + T cells and CD8 + T cells by HLA class II and class I molecules respectively, is the key regulation of optimum immune response against viral infection, and further dictates viral clearance or persistence [12] . HLA allele association with interferon treatment response seems to differ for chronic HCV infections in global populations. This can be attributed to differences in the antigenic determinants of viruses and consequently differences in the HLA molecules involved. The aim of this study is to assess the influence of HLA-class I on response to combination therapy for hepatitis C infection and the predictive value of certain HLA class I alleles with susceptibilities to viral clearance or persistence after Peg-IFN plus ribavirin therapy.
According to logistic regression analysis, Cw17 was considered as the most predictor allele of non response to combined therapy in HCV, as it was the highest significant allele (OR = 16.70; 95% CI: 2.64-105.58; P = 0.003).
Cw17 belongs to group 2 HLA-C molecules which is recognized by killer immunoglobulin like receptors of natural killer cells KIR2DL1 [13] . The killer cell immunoglobulin-like receptors (KIR) control the activation or inhibition of Natural killer (NK) cells by recognition of specific HLA class I ligands, such that target cell cytolysis occurs only when activating signals overcome inhibitory signals. Inhibitory KIR2DL3/HLA-C1 is a relatively weak interaction, whilst inhibitory KIR2DL2/ HLA-C1 and KIR2DL1/HLA-C2 are relatively stronger and therefore the observed correlation with outcome of HCV infection is consistent with the binding data in that weak HLA/KIR interactions are more easily overcome by activating signals than strong HLA and inhibitory KIR gene interaction [5] . In a previous study of the same patient cohort, we demonstrated that KIR2DL1/HLA-C2 was associated with persistent HCV infection [4] .
Regarding the B allele, according to logistic regression analysis, carriers of HLA-B\45 have a 19.35-fold risk of non response to interferon therapy (OR = 19.35; 95% CI: 1.05-357.24; P = 0.04) and can act as the highest predictor allele. Also, carriers of HLA-B\27 have a 15.7 fold risk of non response to therapy (OR = 15.69; 95% CI: 1.179-208.9; P = 0.04), whereas carriers of HLA-B\44 have a 6.535-fold risk of non response to therapy (OR = 6.535; 95% CI: 1.55-27.63; P = 0.01) and can act as the lowest predictor allele. Similarly Fanning et al. [2] demonstrated that persistent HCV infection is associated with the presence of HLA-B\44. On the other hand, a study conducted in Spain revealed the association of HLA B44 with responsiveness to interferon + ribavirin therapy but not when interferon therapy is given alone in hepatitis C with the viral non-1 genotype. [10] .
In the current study, according to logistic regression analysis, HLA-A alleles have a limited role in prediction of response to treatment.
Conclusion
Certain class I alleles can predict the response to HCV treatment, but a large scale study is needed to settle the prevalent HLA alleles as well as other host genetic factors associated with responsiveness in the Egyptian population in order to select candidates for therapy and to reduce the exposure of non responders to the adverse effects of interferon treatment. Thus, Cw17, HLA-B45, and HLA-B27 alleles can predict the response to HCV combined therapy. 
